(Post-pandemic Era)-Global Cancer Antibody Drug Conjugates Market (Sales, Revenue, Price, Gross Profit and Competitors Analysis of Major Market) from 2015-2026
- Report Code : XYZ2131669
- Published On: Nov, 2020
- Category : Medical Devices
- Pages : 118
-
As the world continues to deal with COVID-19, economies are moving into recession, under multiple adverse factors, the GDP of European and American countries in the second quarter suffered a historical contraction. At an annualized rate, the US GDP fell by 32.9% month on month, while the overall GDP of the euro zone fell by 12.1%.
Moreover, the economic prospects of Europe and the United States in the third quarter under the epidemic situation are hardly optimistic. The resumption of work and production not only brought economic data back, but also triggered a rebound in the epidemic situation. At present, the United States is still the 'epicenter' of the global epidemic. The total number of confirmed cases has exceeded 4.8 million, and the epidemic situation in some European countries has also rebounded. Affected by this, more than 20 states in the United States have announced the suspension or withdrawal of part of the economic restart plan. Britain and Italy have also decided to extend the state of emergency. The rebound of the epidemic situation has posed considerable risks to the economic prospects of Europe and the United States.
In the second quarter of this year, US GDP shrank by 9.5% on a month on month basis, or 32.9% at an annual rate, the largest decline since the 1940s. Data show that the sharp decline in personal consumption is the main drag on the U.S. GDP growth in the second quarter.
Compared with the United States, Europe's economic contraction in the second quarter was smaller, but it was also the lowest on record, with Germany and France contracting more than 10%. According to the data released by the Federal Bureau of statistics, Germany's GDP fell by 10.1% in the second quarter after adjusting for prices, seasons and working days, the largest decline since the quarterly economic data were available in 1970.
Thanks to the effective control and policy support of the new epidemic, China's economy rebounded sharply in the second quarter. The growth rate of manufacturing industry, which accounted for about 28% of GDP, rebounded sharply to 4.4% from the negative value in the first quarter. Chinese original equipment manufacturers (OEMs) and suppliers are ramping up production. And there are increased investments in digital footprints in manufacturing. OEMs in other parts of the world are offering incentives to drive sales. Research team published a report for global Cancer Antibody Drug Conjugates market in this environment.
In terms of revenue, this research report indicated that the global Cancer Antibody Drug Conjugates market was valued at USD XXX million in 2019, and it is expected to reach a value of USD XXX million by 2026, at a CAGR of XX % over the forecast period 2021-2026. Correspondingly, the forecast analysis of Cancer Antibody Drug Conjugates industry comprises of China, USA, Japan, India, Korea and South America, with the production and revenue data in each of the sub-segments.
The Novartis aims at producing XX Cancer Antibody Drug Conjugates in 2020, with XX % production to take place in global market, Merck accounts for a volume share of XX %.
Regional Segmentation (Value; Revenue, USD Million, 2015 - 2026) of Cancer Antibody Drug Conjugates Market Include by
China
EU
USA
Japan
India
Southeast Asia
South America
Competitive Analysis; Who are the Major Players in Cancer Antibody Drug Conjugates Market
Novartis
Merck
Roche
AbbVie
UCB
Bristol-Myers Squibb
Stem CentRx
Biogen Idec
Nordic Nanovector
Millennium
Biotest AG
PDL BioPharma
Progenics Pharmaceuticals
Seattle Genetics
Viventia Biotechnologies
AbGenomics Corporation
Helix BioPharma
Major Type of Cancer Antibody Drug Conjugates Covered in report:
First & Second Generation ADCs
Third Generation ADCs
Application Segments Covered in report
Hospitals
Clinics
Other
For any other requirements, please feel free to contact us and we will provide you customized report.
-
With tables and figures helping analyze worldwide (Post pandemic Era) Global Cancer Antibody Drug Conjugates market, this research provides key statistics on the state of the industry and is a valuable source of guidance and direction for companies and individuals interested in the market.
Global Cancer Antibody Drug Conjugates Market Analysis 2020, With Top Companies, Production, Revenue, Consumption, Price and Growth Rate
1 Market Scope1.1 Product Details and Introduction
1.1.1 First & Second Generation ADCs -Product Introduction and Major Manufacturers
1.1.2 Third Generation ADCs -Product Introduction and Major Manufacturers1.2 Market Snapshot
1.2.1 Major Companies Overview
1.2.2 Market Concentration
1.2.3 Six-Year Compound Annual Growth Rate (CAGR)
2 Global Cancer Antibody Drug Conjugates Market Assessment, by Segmentation2.1 Type Breakdown Estimates & Forecast, Sales Volume (2015-2026)
2.2 Type Breakdown Estimates & Forecast, Sales Value (2015-2026)
2.3 Application Breakdown Estimates & Forecast, by Application (2015-2026)
3 Regional Market Analysis3.1 China Cancer Antibody Drug Conjugates Market
3.1.1 Top Companies leading Cancer Antibody Drug Conjugates Development in China (2015-2020)
3.1.2 Sales Value of Major Company in China Market (2015-2020)
3.1.3 China Cancer Antibody Drug Conjugates Price (USD/Unit), by Type (2019-2020)
3.1.4 Sales in China Market, by Type (2015-2026)3.2 EU Cancer Antibody Drug Conjugates Market
3.2.1 Top Companies leading Cancer Antibody Drug Conjugates Development in EU (2015-2020)
3.2.2 Sales Value of Major Company in EU Market (2015-2020)
3.2.3 EU Cancer Antibody Drug Conjugates Price (USD/Unit), by Type (2019-2020)
3.2.4 Sales in EU Market, by Type (2015-2026)3.3 USA Cancer Antibody Drug Conjugates Market
3.3.1 Top Companies leading Cancer Antibody Drug Conjugates Development in USA (2015-2020)
3.3.2 Sales Value of Major Company in USA Market (2015-2020)
3.3.3 USA Cancer Antibody Drug Conjugates Price (USD/Unit), by Type (2019-2020)
3.3.4 Sales in USA Market, by Type (2015-2026)3.4 Japan Cancer Antibody Drug Conjugates Market
3.4.1 Top Companies leading Cancer Antibody Drug Conjugates Development in Japan (2015-2020)
3.4.2 Sales Value of Major Company in Japan Market (2015-2020)
3.4.3 Japan Cancer Antibody Drug Conjugates Price (USD/Unit), by Type (2019-2020)
3.4.4 Sales in Japan Market, by Type (2015-2026)3.5 India Cancer Antibody Drug Conjugates Market
3.5.1 Top Companies leading Cancer Antibody Drug Conjugates Development in India (2015-2020)
3.5.2 Sales Value of Major Company in India Market (2015-2020)
3.5.3 India Cancer Antibody Drug Conjugates Price (USD/Unit), by Type (2019-2020)
3.5.4 Sales in India Market, by Type (2015-2026)3.6 Southeast Asia Cancer Antibody Drug Conjugates Market
3.6.1 Top Companies leading Cancer Antibody Drug Conjugates Development in Southeast Asia (2015-2020)
3.6.2 Sales Value of Major Company in Southeast Asia Market (2015-2020)
3.6.3 Southeast Asia Cancer Antibody Drug Conjugates Price (USD/Unit), by Type (2019-2020)
3.6.4 Sales in Southeast Asia Market, by Type (2015-2026)
3.7 South America Cancer Antibody Drug Conjugates Market
3.7.1 Top Companies leading Cancer Antibody Drug Conjugates Development in South America (2015-2020)
3.7.2 Sales Value of Major Company in South America Market (2015-2020)
3.7.3 South America Cancer Antibody Drug Conjugates Price (USD/Unit), by Type (2019-2020)
3.7.4 Sales in South America Market, by Type (2015-2026)
4 Value Chain (Impact of COVID-19)4.1 Cancer Antibody Drug Conjugates Value Chain Analysis
4.1.1 Upstream
4.1.2 Downstream4.2 COVID-19 Impact on Cancer Antibody Drug Conjugates Industry
4.2.1 Industrial Policy Issued Under the Epidemic Situation4.3 Cost-Under the Epidemic Situation
4.3.1 Cost of Raw Material4.4 Channel Analysis
4.4.1 Distribution Channel-Under the Epidemic Situation
4.4.2 Distributors
5 Regional Market Forecast (2021-2026)5.1 Global Cancer Antibody Drug Conjugates Sales and Growth Rate (2021-2026)
5.2 Global Cancer Antibody Drug Conjugates Sales Value and Growth Rate (2021-2026)
6 Cancer Antibody Drug Conjugates Competitive Analysis6.1 Novartis
6.1.1 Novartis Company Profiles
6.1.2 Novartis Product Introduction
6.1.3 Novartis Cancer Antibody Drug Conjugates Production, Revenue (2015-2020)
6.1.4 SWOT Analysis6.2 Merck
6.2.1 Merck Company Profiles
6.2.2 Merck Product Introduction
6.2.3 Merck Cancer Antibody Drug Conjugates Production, Revenue (2015-2020)
6.2.4 SWOT Analysis6.3 Roche
6.3.1 Roche Company Profiles
6.3.2 Roche Product Introduction
6.3.3 Roche Cancer Antibody Drug Conjugates Production, Revenue (2015-2020)
6.3.4 SWOT Analysis6.4 AbbVie
6.4.1 AbbVie Company Profiles
6.4.2 AbbVie Product Introduction
6.4.3 AbbVie Cancer Antibody Drug Conjugates Production, Revenue (2015-2020)
6.4.4 SWOT Analysis6.5 UCB
6.5.1 UCB Company Profiles
6.5.2 UCB Product Introduction
6.5.3 UCB Cancer Antibody Drug Conjugates Production, Revenue (2015-2020)
6.5.4 SWOT Analysis6.6 Bristol-Myers Squibb
6.6.1 Bristol-Myers Squibb Company Profiles
6.6.2 Bristol-Myers Squibb Product Introduction
6.6.3 Bristol-Myers Squibb Cancer Antibody Drug Conjugates Production, Revenue (2015-2020)
6.6.4 SWOT Analysis
6.7 Stem CentRx
6.7.1 Stem CentRx Company Profiles
6.7.2 Stem CentRx Product Introduction
6.7.3 Stem CentRx Cancer Antibody Drug Conjugates Production, Revenue (2015-2020)
6.7.4 SWOT Analysis
6.8 Biogen Idec
6.8.1 Biogen Idec Company Profiles
6.8.2 Biogen Idec Product Introduction
6.8.3 Biogen Idec Cancer Antibody Drug Conjugates Production, Revenue (2015-2020)
6.8.4 SWOT Analysis
6.9 Nordic Nanovector
6.9.1 Nordic Nanovector Company Profiles
6.9.2 Nordic Nanovector Product Introduction
6.9.3 Nordic Nanovector Cancer Antibody Drug Conjugates Production, Revenue (2015-2020)
6.9.4 SWOT Analysis6.10 Millennium
6.10.1 Millennium Company Profiles
6.10.2 Millennium Product Introduction
6.10.3 Millennium Cancer Antibody Drug Conjugates Production, Revenue (2015-2020)
6.10.4 SWOT Analysis
6.11 Biotest AG
6.12 PDL BioPharma
6.13 Progenics Pharmaceuticals
6.14 Seattle Genetics
6.15 Viventia Biotechnologies
6.16 AbGenomics Corporation
6.17 Helix BioPharma
7 Conclusion
-
The (Post pandemic Era) Global Cancer Antibody Drug Conjugates Market has been segregated into various crucial divisions including applications, types, and regions. Each market segment is intensively studied in the report contemplating its market acceptance, worthiness, demand, and growth prospects. The segmentation analysis will help the client to customize their marketing approach to have a better command of each segment and to identify the most prospective customer base.
Report Objectives / Segmentation Covered :
By Companies / players:
By Regions:
By Type:
By Application:
Frequently asked questions(FAQ's):
New players are entering the (Post pandemic Era) Global Cancer Antibody Drug Conjugates Market, while established companies are changing their business models and strategies. This pattern is likely to continue for the foreseeable future.
According to the report, the (Post pandemic Era) Global Cancer Antibody Drug Conjugates Industry will grow to USD XXX Million by 2030, with a YY% CAGR.
A handful of disruptive trends, nevertheless, will have a contradictory and significant impact on the development of the (Post pandemic Era) Global Cancer Antibody Drug Conjugates Market as well as its distribution among its players
In this highly competitive and rapidly evolving (Post pandemic Era) Global Cancer Antibody Drug Conjugates Industry, top strategic priorities such as innovation, diversification, and M&A would remain consistent.
